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Background: The aim of this study was to investigate the yield of
cervical mediastinoscopy (CM) for pathologically diagnosed non-
small cell lung cancer (NSCLC), with respect to lymph node size on
computed tomography (CT), cell type, and the location of the
primary tumor.
Methods: We reviewed 142 patients who underwent standard cer-
vical mediastinoscopy from April of 1994 to June of 2003 for
pathologically diagnosed NSCLC. The staging yield was determined
by the percentage of “positive” CM (metastatic paratracheal or
subcarinal nodes). Mediastinoscopy was performed when the lymph
node diameter was 1 cm and, since 2001, whenever paratracheal
or subcarinal lymph nodes were clearly seen on CT, regardless of
size. Group A includes patients with lymph nodes on CT of 1 cm.
Group B includes patients with lymph nodes of 1 cm. The 2 test
was used for statistical analysis.
Results: We performed CM on 142 patients. There were 127 men
(89.4%) and 15 women (10.6%). The mean age of the patients was
64.7 years (range, 38–83). The global yield was 28.2% (CM
positive in 40 of 142 cases). The specific yield by groups was as
follows, with respect to lymph node size: group A (lymph nodes1
cm), 37.9%, and group B (lymph nodes 1 cm), 8.5% (p  0.01).
With respect to cell type, 16.3% were squamous tumors, 42.9% were
adenocarcinomas (p 0.01), 45.5% were large-cell carcinomas, and
44.4% were other types. With respect to the location of the primary
tumor and T stage, there were no statistically significant differences
(p  0.09). When only patients with squamous tumors with no
enlarged lymph nodes were considered, staging yield was 3.3% (one
of 30), and 19.6% (20 of 102) of patients with a negative CM had
positive mediastinal lymph nodes at the time of the resection. The
yield was 9.8% (10 of 102 patients) in the territory accessible by CM
at the time of the resection (true false negative), and 9.8% (10 of 102
patients) in the territory not accessible by CM.
Conclusion: Lymph node size and cell type of primary tumors
should be taken into account when selecting patients for staging with
standard MC in NSCLC. In patients with squamous-type tumors
with lymph nodes 1 cm on CT, CM could be avoided because its
low yield.
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At present, surgery is the treatment option that offers thebest survival results for patients with non-small cell lung
cancer (NSCLC). For that reason, it is mandatory to perform
accurate staging of these patients to treat them appropriately.1
The staging of mediastinal lymph nodes is continuously
evolving as new diagnostic tools appear.2,3 The incidence of
pathologic mediastinal nodal metastases (pN2) varies from
24.9% to 62%, depending on the series.4,5 Computed tomog-
raphy (CT) is the most commonly used noninvasive method
for evaluating the mediastinum. However, among the numer-
ous studies on the use of CT as a diagnostic or staging tool,
the values of sensitivity and specificity have been relatively
low.6 In addition, mediastinal nodes with metastasis do not
always appear enlarged on a CT scan. It is believed that about
17% of the patients with resectable NSCLC and no enlarged
mediastinal lymph nodes are really pN2 at the time of
surgery.7 In a prospective study performed by Arita et al.,8
this value rose to 21%. Positron emission tomography (PET)
and endoscopic ultrasound transesophageal needle aspiration
have achieved higher levels of accuracy than CT scans;
however, its use is limited due to high cost and low avail-
ability.9 Cervical mediastinoscopy (CM) is considered an
invasive but safe method for the evaluation of mediastinal
lymph nodes. Nevertheless, there is wide variability in the
criteria for performing CM. Most surgeons perform a CM
when enlarged mediastinal lymph nodes are present on the
CT scan (minor diameter 1 cm). However, other surgeons
routinely perform CM as a part of NSCLC staging, indepen-
dently of radiographic abnormalities.10
We present the results of a review of our experience
with the use of CM between 1994 and 2003, focusing on the
yield of the procedure by groups.
PATIENTS AND METHODS
From April of 1994 to June of 2003, CM was per-
formed in 142 patients with NSCLC. During that period, a
total of 477 patients had surgery for lung cancer. Preoperative
CT scans were performed on all patients. Mediastinal lymph
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nodes were considered enlarged if their minor diameter was
1 cm on CT scan. The CM procedure was carried out
according to a standard technique.11 General anesthesia and
tracheal intubation with an armed single-lumen tube was
employed. Patients were positioned in the dorsal decubitus
position with a roll under the shoulders to provide extension
of the cervical area. A transverse cervicotomy was per-
formed. After the paratracheal fascia opening and finger blunt
dissection along the trachea, the video mediastinoscope was
inserted. The metal blunt-tipped suction-coagulation device
and endoscopic graspers were used simultaneously for dis-
section of mediastinal structures. Endoscopic dissectors were
also used when indicated. Lymph nodes of levels 2, 4, and 7
were identified and accessible for dissection and biopsy.
Lymph nodes could be entirely enucleated in several in-
stances. Fine needle aspiration was performed before biopsy
if doubts existed about the possible vascular nature of the
structure and for cytologic study. Minor hemorrhage was
controlled by coagulation or compression with gauze.
The histologic diagnosis of primary lung cancer
(NSCLC) was obtained with flexible fiber-optic bronchos-
copy or transthoracic needle aspiration under CT guidance.
The location of the tumor (142 cases) was the right upper lobe
(77 cases), the right middle lobe (one case), the right lower
lobe (21 cases), the left upper lobe (27 cases), and the left
lower lobe (16 cases). The T stage (102 cases) was as follows:
10 were pT1, 61 were pT2, 17 were pT3, and 14 were pT4.
Our initial strategy was to perform CM on all the patients
with apparently operable NSCLC and mediastinal lymph
nodes 1 cm on CT scan (group A). Later (since 2001), we
performed CM whenever mediastinal lymph nodes were
present on CT scan, regardless of size (group B). The staging
yield was determined by the percentage of “positive” CM
(metastatic paratracheal or subcarinal nodes) in each group.
We analyzed global yield, yield according to mediastinal
lymph node size on CT scan, yield according to the histologic
origin of the primary NSCLC, and yield according to the
primary lung tumor location.
RESULTS
CM was performed in 142 patients. There were 127
men (89.4%) and 15 women (10.6%). Median age was 64.7
years (range, 38–83).
There was no operative mortality associated with CM.
No significant mediastinoscopy-related complications oc-
curred. The global yield was 28.2% (40 tumor-positive CM of
142 CM procedures). Specific yield by different groups is
shown in Table 1. There were statistical differences (p 
0.01) between lymph node size (groups A and B), and cell
type groups (squamous tumor and adenocarcinoma).
There were no statistical differences between location
of the tumor and T stage. When only patients with squamous
tumors with no enlarged lymph nodes were considered,
staging yield was 3.3% (one of 30 cases) (p  0.01).
Of 102 (19.6%) patients with negative CM, 20 had
positive mediastinal lymph nodes at the time of resection.
Ten of 102 (9.8 %) were not accessible by CM (six aorto-
pulmonary window [level 5], two para-aortic [level 6], one
posterior subcarinal [level 7], and one pulmonary ligament
[level 9]). Ten of 102 (9.8 %) were in the region of CM (three
right lower paratracheal [level 4R], six anterior subcarinal
[level 7], and one pretracheal [level 3]), considered as true
false negative.
DISCUSSION
The future of patients with lung cancer is uncertain,
with global estimated 5-year survival rates of approximately
14%.12 In absolute terms, surgery is the only established
method of cure for lung cancer. It is only possible, however,
in a relatively small proportion of patients with the disease,
mainly NSCLC stages I and II, with 5-year survival rates
between 50% and 70%.13 Mediastinal lymph node involve-
ment, N2 disease, is a factor associated with a negative
prognosis that directly influences the treatment strategy. The
5-year survival rate of patients with NSCLC and pN2 disease
who had complete surgical resection of their tumors varies
TABLE 1. Yield of Cervical Mediastinoscopy According to Mediastinal Lymph Node Size, Cell Type, T Stage, and Laterality
Group
Positive Mediastinoscopy/
No. of Patients Yield (%) p
All the groups 40/142 28.2
Lymph node size Group B (1 cm) 4/47 8.5 0.01
Group A (1 cm) 36/95 37.9
Cell type Squamous 13/80 16.3 0.01
Adenocarcinoma 18/42 42.9
Large-cell carcinoma 5/11 45.5
Others 4/9 44.4
T stage T1 3/12 25 NS (0.5)
T2 20/91 22
T3 4/18 22.2
T4 6/14 42.9
Tumor location Right 32/99 32.3 NS (0.09)
Left 8/43 18.6
Squamous  clinical N0 1/30 3.3
NS, not significant.
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between 19% and 35%, depending on the series.14 The CT
scan is the most widely available and commonly used method
of evaluating the mediastinum in NSCLC staging. Based on
a meta-analysis of 42 studies conducted in 1990, the most
widely accepted criterion for malignant involvement of
lymph nodes is a short axis diameter of 1 cm on a trans-
verse CT scan.15 A recent systematic review by Toloza et al.16
evaluated 20 studies that used standard CT scanning for
staging the mediastinum. The pooled sensitivity was 57% and
the pooled specificity was 82%. Marked heterogeneity in the
sensitivity and specificity of the individual studies was noted.
Subsequent investigations have produced similar findings.
Most surgeons are aware of the importance of tissue confir-
mation when there is mediastinal involvement. In fact, evi-
dence confirms that despite technical advances, no single
imaging method alone is conclusive in evaluating potential
mediastinal involvement in apparently operable lung cancer
and routine clinical conditions.17 Surgical staging of the
mediastinum by CM has been historically the standard pro-
cedure for evaluating mediastinal lymph nodes. Its high
specificity is difficult to be match with imaging methods.
Inaccurate staging results in an understaged patient and in the
loss of the opportunity for preoperative chemotherapy.18
When the patients are up-staged, they may be submitted to an
unnecessary preoperative chemotherapy and lose the oppor-
tunity for curative surgical resection.19
However, CM has limitations; it cannot stage the whole
mediastinum, and its sensitivity in the detection of metastases
in the accessible nodes varies between 79% and 93%.20 In our
series, the sensitivity was 90.2%.
Some authors have reported the results of CM per-
formed in the early stage of NSCLC. Global yield of CM has
varied from 36% to 7% in various series.21–26 In our review,
global yield was 28.2% (n  142). This heterogeneity can be
related to several factors affecting yield that, if identifiable,
could be a guide for establishing widely accepted criteria for
CM indications.27
Primary Tumor Histology
One of the factors that apparently most affects the yield
of CM is NSCLC cell type. In our review, we observed a
global yield of 28.2%. In the adenocarcinoma group, CM was
tumor positive in 42.9% of the cases versus 16.3% in squa-
mous carcinoma (p  0.01). In the large-cell carcinoma
group, 45.5% were tumor positive and 44.4% positive for
other cell types.
Several authors have demonstrated a high rate of pN2
disease in adenocarcinomas. In a study by Choi et al.,26 the
yield of CM was 11.5% in the adenocarcinoma group and
3.3% in the squamous carcinoma group. De Leyn et al.23
demonstrated that the prevalence of positive CM was statis-
tically higher in adenocarcinoma than in squamous carci-
noma. We have only identified one study that found no
differences between the histologic subtypes. Funatsu et al.25
showed a yield of 9% for CM for adenocarcinomas and 7%
for squamous carcinomas. Based on these results, some
authors, such as Nakanishi and Yasumoto,28 are in favor of
the routine surgical mediastinal staging in the cases of ade-
nocarcinoma because in their series this histologic type rep-
resented 54% of the unsuspected pathologic N2 (pN2) that
was diagnosed at thoracotomy. Suzuki et al.29 in their group
of adenocarcinomas, found 17.9% of pN2p-pN3 not seen on
CT scan, concluding that routine CM was a correct staging
strategy in this type of tumor.
According to our experience and based on most of the
published studies, we believe that adenocarcinoma has a
higher tendency to involve mediastinal lymphatic nodes. For
the large-cell carcinoma group, the yield of CM was also high
(45.5%); however, the number of patients was too low to
draw firm conclusions (five of 11).
Mediastinal Lymph Node Size
Many thoracic surgeons hesitate to perform mediasti-
noscopy in patients who have no enlarged mediastinal nodes
on preoperative CT scans.10 On the other hand, there are
studies advocating routine preoperative CM in all patients
with apparently operable NSCLC, even without enlarged
mediastinal lymph nodes.26 The main justification for this
policy is that 17% of the cases in which there are no enlarged
mediastinal nodes on CT scan have pN2 disease at thoracot-
omy.30 The Canadian Lung Oncology Group in 1995 con-
ducted a randomized, controlled trial involving 685 patients
with apparently operable NSCLC who underwent either CM
or CT. Their results showed no advantage in the practice of
routine CM in clinical N0 patients.31 Based on current evi-
dence, patients with apparently operable lung cancer should
all have a CT scan of the chest, and those with nodes 1 cm
should undergo CM, whereas the remainder can proceed
directly to thoracotomy. There is limited evidence that a
combined approach, CT plus CM, in all patients might further
decrease the number or unnecessary thoracotomies. In the
present study, the yield of CM in group B (lymph nodes 1
cm) was 8.5% (n  47), whereas in group A (lymph nodes
1 cm), the yield was 37.9% (n 95) (p 0.01). According
to our data, we consider that the size of mediastinal lymph
nodes influences the yield of CM, and the combination of
squamous carcinoma and lymph nodes 1 cm obviates per-
forming CM given its low yield (3.3%) (p  0.01).
Primary Tumor Location and T Stage
Coughlin et al.22 analyzed their results according to the
location of the primary lung tumors. They reported that
32.65% of right-sided lung tumors had positive mediastinal
lymph nodes at CM, whereas left-sided lung tumors had a
positivity rate of 13.73%. In our study, we obtained similar
results, with a tumor-positive rate of 32.3% for right-sided
lung tumors and 18.6% for left-sided lung tumors, but the
differences were not statistically significant.
Rocha et al.32 documented that the location of lung
cancer (i.e., in the lower lobe) was significant in the incidence
of pN2 and played a role with regard to up-staging. The
incidence of nodal involvement seem to correlate with T
stage. In our series, there were no differences between tumor
location and T stage (Table 1).
CONCLUSION
The size of mediastinal lymph nodes and the histology
of the primary tumor must be taken into account when
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selecting patients for staging CM in NSCLC. The probability
of a CM lymph node–positive biopsy increases when the
primary tumor is an adenocarcinoma or a large-cell carci-
noma and in lymph nodes1 cm. We do not recommend this
approach on patients with squamous-type tumors without
nodal enlargement on CT because of its low yield.
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